Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant stock price declines [2][5][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Skye to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false and misleading statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [5]. - On October 6, 2025, Skye announced that nimacimab did not achieve its primary endpoint in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [6]. Group 3: Investor Participation - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with no impact on their ability to share in any recovery [7]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Skye's conduct [8].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its product, nimacimab, during the specified Class Period from November 4, 2024, to October 3, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Skye Bioscience's defendants misrepresented the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [5]. - Investors who purchased Skye securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by January 16, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional information] NEW YORK, Nov. 21 ...

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for alleged violations of securities laws, specifically related to misleading statements about its drug candidate, nimacimab, and its commercial prospects [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Skye's securities between November 4, 2024, and October 3, 2025, and encourages them to contact the Schall Law Firm before January 16, 2026 [2]. - The complaint alleges that Skye made false and misleading statements regarding the effectiveness of nimacimab and overstated its commercial and clinical prospects [4]. Group 2: Investor Impact - Investors suffered damages when the truth about Skye's drug candidate and its market position was revealed [4]. - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [4].

New York, New York--(Newsfile Corp. - November 20, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2026.SO WHAT: If you purchased Skye securities during the C ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Skye Bioscience, Inc. securities, alleging that the company made materially false and misleading statements regarding its business and the effectiveness of its product, nimacimab, during the class period from November 4, 2024, to October 3, 2025 [1][5]. Group 1: Lawsuit Details - The class action lawsuit has already been filed, and investors who purchased Skye securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5]. - The lawsuit claims that defendants overstated the clinical, regulatory, and commercial prospects of nimacimab, leading to materially false and misleading public statements [5]. Group 2: Participation Information - Investors wishing to join the class action can do so by visiting the Rosen Law Firm's website or contacting their office directly [3][6]. - A lead plaintiff must move the court by January 16, 2026, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Insights - Class actions have been initiated on behalf of stockholders of Skye Bioscience, Inc. and Perrigo Company plc, with deadlines for lead plaintiff petitions set for January 16, 2026 [1][3][7]. Perrigo Company plc - The class period for Perrigo is from February 27, 2023 to November 4, 2025, during which the company allegedly failed to disclose significant issues in its infant formula business acquired from Nestlé, including underinvestment and manufacturing deficiencies [3][4]. - On November 5, 2025, Perrigo announced disappointing financial results for Q3 2025, leading to a reduction in its fiscal year 2025 outlook primarily due to challenges in the infant formula industry [4]. - Following the announcement, Perrigo's stock price dropped by $5.09, or 25.2%, closing at $15.10 per share [4]. Skye Bioscience, Inc. - The class period for Skye is from November 4, 2024 to October 3, 2025, during which the company allegedly made materially false statements regarding the effectiveness and prospects of its drug nimacimab [7]. - On October 6, 2025, Skye disclosed that the nimacimab monotherapy did not achieve its primary endpoint in a clinical study, resulting in a stock price decline of $2.85, or 60%, closing at $1.90 per share [7].

Nov 18, 2025 2:54 PM Eastern Standard Time The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit With the Schall Law Firm Share LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights ...

SAN DIEGO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025. Skye is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors (“GPCRs”) to treat obesity, overweight, and metabolic diseases. The Company’s lead product candidate is nimacimab. Fo ...

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against Skye Bioscience, Inc. (NASDAQ: SKYE) on behalf of investors who suffered significant losses during the specified Class Period from November 4, 2024, to October 3, 2025, due to alleged misleading statements regarding the company's business operations [1][3]. Allegations - The lawsuit claims that Skye Bioscience made materially false and misleading statements about its business, specifically regarding the effectiveness of its drug nimacimab, which was overstated, leading to inflated clinical, regulatory, and commercial prospects [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs must file motions by January 16, 2026, and can choose to remain absent class members without participating in the case [4]. Rosen Law Firm Background - Rosen Law Firm is recognized for its commitment to shareholder rights litigation, having recovered over $1 billion for shareholders since its inception, and operates on a contingency fee basis, meaning shareholders incur no fees or expenses [6].